Is Curis, Inc. (CRIS) a Buy, Sell, or Hold?
Curis, Inc.
NASDAQ:CRIS
$4.73 USD
$0.08 (1.72%)
- Volume
- 45.77K
- Average Volume
- 170.99K
- Market Capitalization
- $9.22M
- P/E Ratio
- -0.20
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $39.00
- Year Low
- $3.60
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.00
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | James Dentzer |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CRIS |
| CUSIP | 231269408 |
| CIK | 0001108205 |
| Web | https://www.curis.com |
| Phone | 617 503 6500 |
| Currency | USD |
| Employees | 24 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.11 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.00 |
| Quick Ratio | 1.00 |
| Cash Ratio | 1.00 |
Sales & Book Value
| Annual Sales | $9.44M |
| Price / Sales | 1.31 |
| Cash Flow | -29.90 |
| Price / Cash Flow | -0.32 |
| Price / Book | 0.36 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 18 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-11.6 |
| Trailing P/E Ratio | -0.20 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-7.58M |
| Net Margin | -299.66% |
| Pretax Margin | -299.66% |
| Return on Equity | 805.67% |
| Return on Assets | -71.30% |
Financials Score
| AltmanZ Score | -61.70 |
| Piotroski Score | 1.00 |
| Working Capital | 27K |
| Total Assets | 29.69M |
| Ebit | -20.59M |
| Market Cap | 9.06M |
| Total Liabilities | 16.98M |
Poll Results
About Curis, Inc. (NASDAQ:CRIS) Stock
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 an ... d TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Curis Consents First Six Patients in TakeAim CLL Study
2026-07-06 09:30:00
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study.
2026-06-26 10:00:00
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Rever
2026-06-26 09:42:00
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December 2026; Stockholders approve reverse stock split LEXINGTON, Mass., June 26, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that eleven clinical sites have been initiated and are now open for patient enrollment in its Phase 2 TakeAim CLL study evaluating emavusertib in combination with zanubrutinib in patients with Chronic Lymphocytic Leukemia.
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript
2026-05-13 04:20:45
Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript
Curis Provides First Quarter 2026 Business Update
2026-05-12 16:00:00
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.
2026-05-05 17:11:00
LEXINGTON, Mass., May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its first quarter 2026 financial and operating results on Tuesday, May 12, 2026, at 4:00 p.m.
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
2026-04-28 09:46:12
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago.
Frequently Asked Questions
-
What is the current Curis, Inc. (CRIS) stock price?
-
Curis, Inc.(NASDAQ:CRIS) stock price is $4.73 in the last trading session. During the trading session, CRIS stock reached the peak price of $39 while $3.6 was the lowest point it dropped to. The percentage change in CRIS stock occurred in the recent session was 1.72% while the dollar amount for the price change in CRIS stock was $0.08.
-
CRIS's industry and sector of operation?
-
The NASDAQ listed CRIS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CRIS?
-
Jonathan Zung | Chief Development Officer
Rachel Blasbalg | Senior Director of Human Resources
Robert E. Martell | Chief Scientific Officer
Nancy Soohoo | Vice President & General Counsel
Ahmed Hamdy | Chief Medical Officer -
How many employees does CRIS have?
-
Number of CRIS employees currently stands at 24. CRIS operates from Building C, Lexington, MA 02421, US.
-
Link for CRIS official website?
-
Official Website of CRIS is: https://www.curis.com
-
How do I contact CRIS?
-
CRIS could be contacted at phone #617 503 6500 and can also be accessed through its website. CRIS operates from Building C, Lexington, MA 02421, US.
-
How many shares of CRIS are traded daily?
-
The average number of CRIS shares traded daily for last 3 months was 170.99K.
-
What is the market cap of CRIS currently?
-
The market value of CRIS currently stands at $9.22M with its latest stock price at $4.73